Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer’s Disease has been published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS).
The company noted that the publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, is the second related to the intranasal administration of anti-CD3 monoclonal antibody to be published in PNAS this year.
“I am proud to be the senior author on this seminal publication showing that anti-CD3 mAb mitigates Alzheimer’s disease in a rodent model,” commented Dr. Howard Weiner, chairman of Tiziana’s Scientific Advisory Board and Professor of Neurology at the Harvard Medical School.
“Remarkably, we found this benefit occurred independent of reduction of amyloid beta plaque in the brain.”
He said that this finding demonstrates a unique mechanism of action that can now be tested in humans using foralumab in which microglia would be modulated by inducing T cells in the periphery that migrate to the brain.
“This represents a unique approach to treating Alzheimer’s disease that could also potentially be employed in combination with anti-amyloid therapy,” Dr. Weiner said.
“The neuromodulation of the T cell inflammatory response we observed in the brains of Alzheimer’s mice is consistent with multiple sclerosis research we have conducted at the Ann Romney Center and validates our scientific rationale for testing foralumab in Alzheimer’s patients after the recent Investigational New Drug (IND) clearance by the United States Food and Drug Administration (FDA).”
Tiziana’s acting CEO Gabriele Cerrone added: “We believe this scientific publication, along with the groundbreaking research continuously being conducted by our partners at Brigham and Women’s Hospital led by Dr. Weiner, greatly increases the utilization potential of our foralumab portfolio.”
Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie